Last reviewed · How we verify
NP-G2-044 Combination therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
NP-G2-044 Combination therapy (NP-G2-044 Combination therapy) — Novita Pharmaceuticals, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NP-G2-044 Combination therapy TARGET | NP-G2-044 Combination therapy | Novita Pharmaceuticals, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NP-G2-044 Combination therapy CI watch — RSS
- NP-G2-044 Combination therapy CI watch — Atom
- NP-G2-044 Combination therapy CI watch — JSON
- NP-G2-044 Combination therapy alone — RSS
Cite this brief
Drug Landscape (2026). NP-G2-044 Combination therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/np-g2-044-combination-therapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing